Latest Entries
General

The OECD Blue Sky Forum on Science and Innovation indicators helded in Ghent, Belgium, Monday-Wednesday, September 19 – 21. Together with Susana Borrás, Charles presented a paper entitled: “Conceptual Underpinnings for Innovation Policy Design ‐ Instruments and Indicators in Context”. The paper can be downloaded here. The home page of this long-term and high-profile conference is: … Continue reading

General

SPRU 50 Year’s Conference at Sussex University

The SPRU 50 Year’s Conference is on, September 7 – 9 at Sussex University, Brighton, UK. At that conference, Charles presented a paper entitled “The Swedish National Innovation Council – Governance to replace linearity with holism in innovation policy?”. The link to the conference is: http://www.sussex.ac.uk/spru/about/50years/conference and the link to the paper is http://wp.circle.lu.se/upload/CIRCLE/workingpapers/201624_edquist.pdf Continue reading

General

State capital risk provision in the National Innovation Council (NIC)

There seems to have been a “spontaneous” tendency for public innovation funding organizations to drift into funding in later stages in the innovation process – instead of concentrating on the early stages, where innovating companies do not yet have any sales. The provision of this funding did compete with private providers of capital, which may … Continue reading

General

Functional public procurement in the National Innovation Council (NIC)

The Swedish government took a decision to adopt the National Procurement Strategy in late June 2016 – Ardalan Shekarabi is responsible Minister. Functional procurement is an important element in that strategy. What is described in the procurement documents (förfrågningsunderlagen) in such procurement is functions or solutions to problems rather than products (goods and services). This … Continue reading

IMI Final Report
New!

IMI Final Report

The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the … Continue reading